Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Long-term cohort studies

Topic: Risk, prevention and care in population studies

Plain-language summary

Introduction We created global rating scoring rules for the CDR ® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD. Methods The CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 40 participants. This study created global rating scoring rules for the CDR plus NACC FTLD to detect and track early frontotemporal lobar degeneration. It is about a clinical rating tool for frontotemporal dementia, not about treating, curing or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Miyagawa, T., Brushaber, D., Syrjanen, J., Kremers, W., Fields, J., Forsberg, L. K., et al. (2020). Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.12033

Vancouver

Miyagawa T, Brushaber D, Syrjanen J, Kremers W, Fields J, Forsberg LK, et al. Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2020. doi:10.1002/alz.12033. PMID: 31914218.

BibTeX

@article{miyagawa2020-31914218,
  author  = {Miyagawa, T. and Brushaber, D. and Syrjanen, J. and Kremers, W. and Fields, J. and Forsberg, L. K. and Heuer, H. W. and Knopman, D. and others},
  title   = {{Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2020},
  doi     = {10.1002/alz.12033},
  pmid    = {31914218},
  url     = {https://doi.org/10.1002/alz.12033}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study created global rating scoring rules for the CDR plus NACC FTLD to detect and track early frontotemporal lobar degeneration. It is about a clinical rating tool for frontotemporal dementia, not about treating, curing or preventing Alzheimer's disease.

Study details

How this study scored 68/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 68 of 100.68 of 100 points earned32 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 1 / 4 40 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 165 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 20.6 citations a year over 8 year(s) since 2020
Impact for its field and year 4 / 6 Cited 12.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 24 other studies in this library
Still being cited 3 / 4 Cited 84 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Zbigniew K. Wszołek: h-index 112 (OpenAlex, whole career)
Institution's track record 3 / 3 University of Washington: institution h-index 3,540 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 25 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31914218)
Free to read 0 / 2 Behind a paywall — scores zero
Total 68 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.

Later studies that cite this one

24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Long-term cohort studies from nearby years

Also in Long-term cohort studies

54 studies in the library are filed under Long-term cohort studies with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Long-term cohort studies hub.

Similar studies

More on Long-term cohort studies

See all studies in Long-term cohort studies →